BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the company will present nine abstracts from its hereditary angioedema (HAE) portfolio at the 2026 American Academy of Allergy, ...

BioCryst Pharmaceuticals (NasdaqGS:BCRX) has agreed to acquire Astria Therapeutics. The deal adds a Phase 3 hereditary angioedema therapy candidate to BioCryst's rare disease pipeline. The transaction ...

RESEARCH TRIANGLE PARK, N.C., Feb. 05, 2026 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the company will report its fourth quarter 2025 financial results on ...

—Company achieved operating profit in 2024 (not including stock-based compensation) and expects to approach quarterly EPS profitability/positive cash flow in 2H 2025— —New drug application planned in ...

BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) is one of the stocks Jim Cramer commented on. A caller asked if the current ...

BioCryst's main value driver, ORLADEYO, is already profitable in its second year on the market and generated over $250 million in revenue in 2022. ORLADEYO is successfully differentiating itself in a ...

BioCryst Pharmaceuticals (BCRX) appears an attractive pick, as it has been recently upgraded to a Zacks Rank #1 (Strong Buy). An upward trend in earnings estimates -- one of the most powerful forces ...

For the quarter, BioCryst managed to increase its revenue by 41% to $131.5 million. The company also narrowed its generally accepted accounting principles (GAAP) net loss; this came in at $26.8 ...

Astria Therapeutics, Inc. (Nasdaq: ATXS) today announced that at the special meeting of Astria's stockholders held on January 21, 2026, Astria's stockholders voted to approve the acquisition of Astria ...

DURHAM – BioCryst Pharmaceuticals has struck a licensing deal with a Georgia based company for a treatment targeting vision loss among those suffering diabetic macular edema, or DME. Clearside ...

Biotech stocks rebounded in 2025. Wedbush’s Laura Chico explains why rare disease catalysts and upcoming data could shape the ...

BOSTON, January 21, 2026--(BUSINESS WIRE)--Astria Therapeutics, Inc. (Nasdaq: ATXS) today announced that at the special meeting of Astria’s stockholders held on January 21, 2026, Astria’s stockholders ...